Entasis Therapeutics Holdings Inc (ETTX) Stock
ETTX is no longer traded. Entasis Therapeutics Holdings was delisted from the Nasdaq in July 2022.
Prices on this page are historical; the last trade was July 8, 2022 at $2.19.
Entasis Therapeutics Holdings stock price history
ETTX final trading statistics
- Final close
- $2.19
- Final trading day
- Jul 8, 2022
- Market cap at delisting
- $104.80M
- Shares outstanding
- 47.85M
- Final 52-week range
- $1.40 – $3.88
- Avg. volume (final 3 mo.)
- 233,086
- All-time high (split-adj.)
- $10.88 · Sep 2018
- All-time low (split-adj.)
- $1.45 · Feb 2022
- Return since IPO
- -79.5%
- Beta
- 1.33
- Book value / share
- $0.35
- Price / book
- 6.29
Entasis Therapeutics Holdings annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $0.00 | -$47.1M | -$1.09 |
| FY2020 | $0.00 | -$50.5M | -$2.43 |
| FY2019 | $7.00M | -$43.9M | -$3.34 |
| FY2018 | $5.00M | -$33.0M | -$22.36 |
| FY2017 | $0.00 | -$29.9M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Entasis Therapeutics Holdings Inc
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.
Entasis Therapeutics Holdings stock FAQ
What happened to Entasis Therapeutics Holdings stock?
Entasis Therapeutics Holdings stock was delisted from the Nasdaq. Its final close was $2.19 on July 8, 2022.
Is ETTX stock still trading?
No. ETTX was delisted from the Nasdaq in July 2022 and no longer trades on a U.S. exchange.
What was the last price of ETTX stock?
ETTX closed at $2.19 on its final trading day, July 8, 2022, for a market value of about $104.80M.
What were Entasis Therapeutics Holdings's revenue and earnings in its last full fiscal year?
Entasis Therapeutics Holdings reported revenue of $0.00 and net income of -$47.1M in fiscal 2021, its last full year as a public company.
When did Entasis Therapeutics Holdings go public?
Entasis Therapeutics Holdings Inc stock began trading on September 26, 2018.